Tag: JAB-2485

Jacobio Pharma doses first patient with Aurora A inhibitor JAB-2485 in phase 1/2a trial

businessnewstoday- January 8, 2023

Jacobio Pharma said that it has completed the first patient dosage of Aurora A inhibitor JAB-2485, its in-house R&D drug candidate, in a phase 1/2a ... Read More